Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
September 16 2022 - 4:30PM
Myovant Sciences (NYSE: MYOV), a biopharmaceutical
company that aspires to redefine care for women and for men through
purpose-driven science, empowering medicines, and transformative
advocacy, today announced that it approved equity awards for 7 new
employees with a grant date of September 15,
2022 pursuant to Myovant’s 2020 Inducement Plan. The equity
awards were granted to the employees joining Myovant in
accordance with NYSE’s Listed Company Manual
Rule 303A.08.
The new employees received, in the aggregate, restricted stock
units (RSUs) to purchase 37,700 common shares of Myovant.
One-fourth of the shares underlying each employee’s RSU will vest
on the one-year anniversary of the grant date, with the balance of
the common shares vesting in twelve equal quarterly installments
thereafter, in each case, subject to each such employee’s continued
employment with Myovant on such vesting dates. The RSUs
are subject to the terms and conditions of the 2020 Inducement Plan
and the applicable RSU agreements.
ABOUT MYOVANT SCIENCESMyovant
Sciences aspires to redefine care for women and for men
through purpose-driven science, empowering medicines, and
transformative advocacy. Founded in 2016, Myovant has
executed five successful Phase 3 clinical trials across oncology
and women’s health leading to three regulatory approvals by
the U.S. Food and Drug Administration (FDA) for men with
advanced prostate cancer, women with heavy menstrual bleeding
associated with uterine fibroids, and premenopausal women with
moderate to severe pain associated with endometriosis,
respectively. Myovant also has received regulatory
approvals by the European Commission (EC) and
the United Kingdom Medicines and Healthcare Products
Regulatory Agency (MHRA) for women with symptomatic uterine
fibroids and for men with advanced hormone-sensitive prostate
cancer. Myovant has a supplemental New Drug Application under
review with the FDA for updates to the United States Prescribing
Information (USPI) based on safety and efficacy data from the Phase
3 LIBERTY randomized withdrawal study (RWS) of MYFEMBREE in
premenopausal women with heavy menstrual bleeding due to uterine
fibroids for up to two years. Myovant also is conducting
a Phase 3 study to evaluate the prevention of pregnancy in women
with uterine fibroids or endometriosis. Myovant also is
developing MVT-602, an investigational oligopeptide kisspeptin-1
receptor agonist, which has completed a Phase 2a study for female
infertility as part of assisted reproduction. Sumitovant
Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Pharma Co.,
Ltd., is Myovant’s majority shareholder. For more information,
please visit www.myovant.com. Follow @Myovant on
Twitter and LinkedIn.
Myovant Sciences ContactsInvestor
Contact:Uneek MehraChief Financial and Business
OfficerMyovant Sciences, Inc.investors@myovant.com
Media Contact:Noelle Cloud DuganVice President,
Corporate CommunicationsMyovant Sciences,
Inc.media@myovant.com
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Jul 2023 to Jul 2024